GlaxoSmithKline S.A.E Statistics
Total Valuation
GlaxoSmithKline S.A.E has a market cap or net worth of EGP 3.40 billion. The enterprise value is 3.27 billion.
Market Cap | 3.40B |
Enterprise Value | 3.27B |
Important Dates
The last earnings date was Thursday, November 14, 2024.
Earnings Date | Nov 14, 2024 |
Ex-Dividend Date | Jul 18, 2024 |
Share Statistics
GlaxoSmithKline S.A.E has 83.51 million shares outstanding. The number of shares has increased by 0.57% in one year.
Current Share Class | n/a |
Shares Outstanding | 83.51M |
Shares Change (YoY) | +0.57% |
Shares Change (QoQ) | -0.34% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 2.43M |
Valuation Ratios
The trailing PE ratio is 28.52.
PE Ratio | 28.52 |
Forward PE | n/a |
PS Ratio | 1.21 |
PB Ratio | 1.75 |
P/TBV Ratio | n/a |
P/FCF Ratio | 96.04 |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.37, with an EV/FCF ratio of 92.40.
EV / Earnings | 27.38 |
EV / Sales | 1.16 |
EV / EBITDA | 5.37 |
EV / EBIT | 5.86 |
EV / FCF | 92.40 |
Financial Position
The company has a current ratio of 1.75, with a Debt / Equity ratio of 0.04.
Current Ratio | 1.75 |
Quick Ratio | 0.90 |
Debt / Equity | 0.04 |
Debt / EBITDA | 0.13 |
Debt / FCF | 2.33 |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 6.16% and return on invested capital (ROIC) is 17.93%.
Return on Equity (ROE) | 6.16% |
Return on Assets (ROA) | 10.02% |
Return on Capital (ROIC) | 17.93% |
Revenue Per Employee | 3.51M |
Profits Per Employee | 149,442 |
Employee Count | 800 |
Asset Turnover | 0.77 |
Inventory Turnover | 1.63 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +27.23% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +27.23% |
50-Day Moving Average | 38.81 |
200-Day Moving Average | 33.53 |
Relative Strength Index (RSI) | 50.01 |
Average Volume (20 Days) | 113,524 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GlaxoSmithKline S.A.E had revenue of EGP 2.81 billion and earned 119.55 million in profits. Earnings per share was 1.43.
Revenue | 2.81B |
Gross Profit | 1.18B |
Operating Income | 582.85M |
Pretax Income | 283.25M |
Net Income | 119.55M |
EBITDA | 620.97M |
EBIT | 582.85M |
Earnings Per Share (EPS) | 1.43 |
Balance Sheet
The company has 212.21 million in cash and 82.48 million in debt, giving a net cash position of 129.74 million or 1.55 per share.
Cash & Cash Equivalents | 212.21M |
Total Debt | 82.48M |
Net Cash | 129.74M |
Net Cash Per Share | 1.55 |
Equity (Book Value) | 1.93B |
Book Value Per Share | 23.23 |
Working Capital | 1.28B |
Cash Flow
In the last 12 months, operating cash flow was 120.87 million and capital expenditures -85.45 million, giving a free cash flow of 35.43 million.
Operating Cash Flow | 120.87M |
Capital Expenditures | -85.45M |
Free Cash Flow | 35.43M |
FCF Per Share | 0.42 |
Margins
Gross margin is 41.87%, with operating and profit margins of 20.74% and 4.25%.
Gross Margin | 41.87% |
Operating Margin | 20.74% |
Pretax Margin | 10.08% |
Profit Margin | 4.25% |
EBITDA Margin | 22.09% |
EBIT Margin | 20.74% |
FCF Margin | 1.26% |
Dividends & Yields
This stock pays an annual dividend of 0.75, which amounts to a dividend yield of 1.85%.
Dividend Per Share | 0.75 |
Dividend Yield | 1.85% |
Dividend Growth (YoY) | -80.00% |
Years of Dividend Growth | 2 |
Payout Ratio | 61.44% |
Buyback Yield | -0.57% |
Shareholder Yield | 1.28% |
Earnings Yield | 3.51% |
FCF Yield | 1.04% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |